Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2015 · 10-K
Revenue$43.69M$43.69M+39.9% vs Q4 2014 Net Income$6.85M$6.85M+81.0% vs Q4 2014 EPS Diluted$0.14$0.14+55.6% vs Q4 2014 Operating Incomederived$7,881,000+53.8% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Operating Cash Flowderived$19,927,000+218.2% Free Cash Flowderived$19,063,000+210.2% Margins · derivedOperating margin18.0%+1.6 pt vs Q4 2014
Net margin15.7%+3.6 pt vs Q4 2014
ended Dec 31, 2015 · filed Mar 9, 2016 · 69 d after period end